Drug Trial Radar · NCT01961921
The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)
Last checked: Nov 19, 2026Latest source record: Apr 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
27
Actual
Start
Oct 2013
Primary completion
Jul 2016
Study completion Aug 2016
Sponsor
- Lead sponsor
- Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
- Sponsor type
- Industry
- First posted
- Oct 14, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and tolerability of long-term dosing with ALN-TTR02 (patisiran) in patients with transthyretin (TTR) mediated amyloidosis (ATTR).
Conditions
- TTR-mediated Amyloidosis
Interventions
ALN-TTR02 (patisiran) administered by intravenous (IV) infusionDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Number of Participants Experiencing Adverse Events (AEs), Serious Adverse Events (SAEs) and Study Drug DiscontinuationTime frame: From Baseline up to 56 days post last dose
Locations
9 sites in 7 countries. Site status is shown where the registry gives one.
Clinical Trial Site
Boston, Massachusetts
Clinical Trial Site
Rio de Janeiro, Brazil
Clinical Trial Site
Le Kremlin-Bicêtre, France
Clinical Trial Site
Marseille, France
Clinical Trial Site
Münster, Germany
Clinical Trial Site
Lisbon, Portugal
Clinical Trial Site
Porto, Portugal
Clinical Trial Site
Palma de Mallorca, Spain
Clinical Trial Site
Umeå, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.